DATE: February 6, 2000

SHEET _1_ of _1_

F	orm	PTC	- 1449	(Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERC

(Modified)

(37 CFR 1.98 (b))

PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

SERIAL NO.

6587.US.O1 APPLICANT 09/438,994

S. L. Krill, et al.

FILING DATE

GROUP

November 12 , 1999

1614

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
Her	A1	5	8	8	9	0	5	1	03/30/99	Chen, et al.			
-,1		Г											
					Π								

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

`		DOCUMENT NUMBER							PUBLIC- ATION	COUNTRY OR	SUB	TRA LAT	
100		l							DATE	PATENT OFFICE CLASS	CLASS	YES	NO
ASSEX .	B1	0	8	5	2	1	4	0	08.07.98	EP			
Aux	B2	9	7	4	6	2	2	2	11.12.97	WO			
RUP	B3	9	7	0	6	7	8	1	27.02.97	WO		Х	
											-		

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

AGR	C1	W. L. Chiou, et al., "Pharmaceutical Applications of Solid Dispersion Systems", JOURNAL OF PHARMACEUTICAL SCIENCES, 60 (9), (1971), 1281-1302.
HER	C2	J. L. Ford, "The Current Status of Solid Dispersions", PHARM ACTA HELV, 61. Nr. 3, (1986) 69-88.
AEP	C3	B. J. Aungst, et al., "Improved Oral Bioavailability of an HIV Protease Inhibitor Using Celucire 44/14 and Labrasol Vehicles", B. T. GATTETOSSE, 87, (1994), 49-54.
AGA	C4	B. J. Aungst, et al., "Amphiphilic Vehicles Improve the Oral Bioavailability of a Poorly Soluble HIV Protease Inhibitor at High Doses", INTERNATIONAL JOURNAL OF PHARMACEUTICS, 156 (1997), 79-88.

EXAMINER

DATE CONSIDERED

7000

EXAMINER: Initial ditation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)